Galectin Therapeutics CFO Purchases $4,550 in Stock (GALT)
Galectin Therapeutics (NASDAQ:GALT) CFO Jack W. Callicutt acquired 1,000 shares of Galectin Therapeutics stock in a transaction that occurred on Thursday, August 14th. The stock was purchased at an average cost of $4.55 per share, for a total transaction of $4,550.00. Following the purchase, the chief financial officer now directly owns 1,260 shares of the company’s stock, valued at approximately $5,733. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.
Galectin Therapeutics (NASDAQ:GALT) traded up 1.52% on Friday, hitting $4.68. The stock had a trading volume of 287,537 shares. Galectin Therapeutics has a one year low of $4.28 and a one year high of $19.11. The stock’s 50-day moving average is $10.47 and its 200-day moving average is $12.81. The company’s market cap is $103.2 million.
Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, analysts predict that Galectin Therapeutics will post $-0.95 earnings per share for the current fiscal year.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.